The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLIII.ag

Obstructive airway dysfunction (see also IVc, XVx)

Publications

Bruguera-Àvila N, Sánchez-Martínez E, Garcia-Olivé I, Pérez-Ochoa JF, Martínez-Barenys C, Ruiz-Manzano J

Obliterating bronchiolitis in a patient treated with (D)-penicillamine.

Archivos de bronconeumologia 2013 Sep;49;411-2 — 2013 Sep — 411-2

Camus P

[The respiratory complications of D-Penicillamine therapy (author's transl)].

Revue francaise des maladies respiratoires 1982;10;7-20 — 1982 — 7-20

Wolfe F, Schurle DR, Lin JJ, Polland SM, Smith TW, Montgomery-Short R, James DL

Upper and lower airway disease in penicillamine treated patients with rheumatoid arthritis.

The Journal of rheumatology 1983 Jun;10;406-10 — 1983 Jun — 406-10

van de Laar MA, Westermann CJ, Wagenaar SS, Dinant HJ

Beneficial effect of intravenous cyclophosphamide and oral prednisone on D-penicillamine-associated bronchiolitis obliterans.

Arthritis and rheumatism 1985 Jan;28;93-7 — 1985 Jan — 93-7